Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rebastinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 known ✓ | P00519 | 7/20 | 0.88 |
| ▸ | BRAF | P15056 | 8/20 | 0.88 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.88 |
| ▸ | SRC | P12931 | 3/20 | 0.88 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.88 |
| ▸ | AXL | P30530 | 2/20 | 0.88 |
| ▸ | PLK4 | O00444 | 1/20 | 0.88 |
| ▸ | ACOX3 | O15254 | 1/20 | 0.88 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.88 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.88 |
| ▸ | JAK2 | O60674 | 1/20 | 0.88 |
| ▸ | ERN1 | O75460 | 1/20 | 0.88 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.88 |
| ▸ | STK10 | O94804 | 1/20 | 0.88 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.88 |
| ▸ | RAF1 | P04049 | 1/20 | 0.88 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.88 |
| ▸ | LCK | P06239 | 1/20 | 0.88 |
| ▸ | FYN | P06241 | 1/20 | 0.88 |
| ▸ | CDK1 | P06493 | 1/20 | 0.88 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rebastinib SCHEMBL29716650 | 1.00 | BRAF (0.88) | BRAFABL1MAPK14SRCRIPK1 | |
| Rebastinib SCHEMBL29733458 | 1.00 | BRAF (0.88) | BRAFABL1MAPK14SRCRIPK1 | |
| Rebastinib SCHEMBL2034290 | 0.94 | BRAF (1.00) | BRAFABL1MAPK14SRCRIPK1 | |
| Rebastinib SCHEMBL30499050 | 0.94 | BRAF (1.00) | BRAFABL1MAPK14SRCRIPK1 | |
| Rebastinib SCHEMBL29354367 | 0.94 | BRAF (1.00) | BRAFABL1MAPK14SRCRIPK1 | |
| Rebastinib SCHEMBL29733447 | 0.94 | BRAF (1.00) | BRAFABL1MAPK14SRCRIPK1 | |
| Rebastinib SCHEMBL29733460 | 0.93 | BRAF (0.99) | BRAFABL1MAPK14SRCRIPK1 | |
| Rebastinib SCHEMBL2026623 | 0.93 | BRAF (0.99) | BRAFABL1MAPK14SRCRIPK1 | |
| Rebastinib SCHEMBL12079461 | 0.89 | BRAF (0.91) | BRAFABL1MAPK14SRCRIPK1 | |
| SCHEMBL2024402 | 0.88 | BRAF (0.89) | BRAFABL1MAPK14SRCRIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3875078-A1 | COMPOUNDS FOR THE TREATMENT OF COVID-19 | Dompe' Farmaceutici S.P.A. (IT) | 2021-09-08 | — | — | EP | claimed |
| EP-3875078-A1 | COMPOUNDS FOR THE TREATMENT OF COVID-19 | Dompe' Farmaceutici S.P.A. (IT) | 2021-09-08 | — | — | EP | disclosed |
| US-20190091217-A1 | METHODS FOR INHIBITING TIE-2 KINASE USEFUL IN THE TREATMENT OF CANCER | DECIPHERA PHARMACEUTICALS LLC (US) | 2019-03-28 | — | — | US | disclosed |
| US-20170209428-A1 | METHODS FOR INHIBITING TIE-2 KINASE USEFUL IN THE TREATMENT OF CANCER | DECIPHERA PHARMACEUTICALS, LLC | 2017-07-27 | — | — | US | disclosed |
| US-9457019-B2 | Methods for inhibiting tie-2 kinase useful in the treatment of cancer | DECIPHERA PHARMACEUTICALS, LLC (US) | 2016-10-04 | — | — | US | disclosed |
| EP-3065549-A1 | METHODS FOR INHIBITING TIE2 KINASE USEFUL IN THE TREATMENT OF CANCER | Deciphera Pharmaceuticals, LLC (US) | 2016-09-14 | — | — | EP | disclosed |
| US-20150246033-A1 | METHODS FOR INHIBITING TIE-2 KINASE USEFUL IN THE TREATMENT OF CANCER | DECIPHERA PHARMACEUTICALS, LLC | 2015-09-03 | — | — | US | disclosed |
| WO-2015069266-A1 | METHODS FOR INHIBITING TIE2 KINASE USEFUL IN THE TREATMENT OF CANCER | FLYNN DANIEL L (US) | 2015-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190091217-A1 | METHODS FOR INHIBITING TIE-2 KINASE USEFUL IN THE TREATMENT OF CANCER | TIE1, TEK, FLT4 | ABL1 19/4885BRAF 873/4885MAPK14 907/4885 |
| US-20150246033-A1 | METHODS FOR INHIBITING TIE-2 KINASE USEFUL IN THE TREATMENT OF CANCER | TIE1, TEK, FLT4 | ABL1 19/4885BRAF 873/4885MAPK14 907/4885 |
| US-20170209428-A1 | METHODS FOR INHIBITING TIE-2 KINASE USEFUL IN THE TREATMENT OF CANCER | TIE1, TEK, FLT4 | ABL1 19/4885BRAF 873/4885MAPK14 907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.